Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Looks like another massive 2M plus volume day at PDSB.
Over $20M up on the day, so £800k to NSCI and we actually went down.
I am so looking forward to the day that PDSB just goes vertical and we double on the news.
AIM and the UK market in general is the worst I have ever seen in 30 years.
Looking forward to seeing these deals announced.
Following the Investment and conversion of the 2023 CLA (assuming all accrued interest is converted), the Company's direct stake in Glycotest will be 55.90 per cent, alongside Fosun's interest of 34.75 per cent. and the 2023 CLA interest of 6.16 per cent.
The proceeds of the Investment will, inter alia, support Glycotest in the development and validation of its assays ahead of commercial launch. Such validation is possible after the completion in 2023 of subject enrolment and sample collection in Glycotest's clinical validation study, providing a valuable biobank which the company believes now represents one of the world's largest collections of liver cancer blood samples. Glycotest is in advanced negotiations with a number of prospective collaboration partners, further details of which shall be reported in due course.
Those options were from the 382K he got when he joined NSCI.
Exercise price was 45p so easy money for NSCI.
He also had 254K at £1.24p.
Well things sound healthy at least ?!
January Portfolio & Investment News
After a dynamic start to 2024, we are excited to share the January highlights from the EMV Capital and NetScientific PLC group deep tech portfolio:
▶ Glycotest, Inc., the US based liver diagnostics company, has closed a $1m follow-on investment from Fosun 复星 to support the development and validation of its assays ahead of commercial launch.
▶ Wanda Health, the intelligent platform for Remote Patient Monitoring and Virtual Care, has achieved ISO 13485:2016 certification for its Medical Device Quality Management System.
▶ Q-Bot Ltd, the developer of robots for use in the construction and retrofit industry, has been featured in the UK Green Building Council (UKGBC) Trends in Sustainable Solutions in the Built Environment Report 2023.
▶ DeepTech Recycling, the plastic recycling technology business, is progressing its commercial operations with new strategic hires and a transition into new facilities following its £1m first close in December.
▶ Ventive Limited, the heat pump and passive air ventilation specialist, is scaling up its team with two senior hires following a successful first closing of its investment programme in 2023.
▶ ProAxsis, the respiratory diagnostics company, has strengthened its Board with the appointment of Steve Myint, an internationally experienced clinician with board level experience in biotech and pharmaceuticals, as a Non-Executive Director. This follows the appointment of Alan Markey as a Chairman in 2023.
▶ PointGrab, a smart sensing solution for commercial real estate technology industries, has recently welcomed Amir EINAV, an experienced business leader with a strong GTM background, as its CEO, and David Gelber as its Chairman.
▶ Martlet Capital has participated in £3.5m funding round for OctaiPipe, the end-to-end Edge AI platform, and £5.5m funding round for Xampla, a cleantech company advancing plant-based, biodegradable material that aims to replace plastic.
▶ SageTech Medical attended the Association of Anaesthetists Winter Scientific Meeting, showcasing its solutions at the Dräger stand.
👇 Subscribe to our newsletter for more insights and updates: https://lnkd.in/etxzjW6J
IMHO they are used by MMs to guide prices between the brokers rather than any punter trades.
An interesting trading day so far ...... !!
Why oh why would somebody buy/sell 1 or 3 ?! Why go to that effort ?! 😂😂
Biffa I added to my decent holding today.
Suspect today may prove to have been the last day to add below 63 pence.
So our holding in PDSB has gone up by £2M since it's low a few weeks back and we have had confirmation that our £10M Glycotest investment is still going strong.
The proceeds of the Investment will, inter alia, support Glycotest in the development and validation of its assays ahead of commercial launch. Such validation is possible after the completion in 2023 of subject enrolment and sample collection in Glycotest's clinical validation study, providing a valuable biobank which the company believes now represents one of the world's largest collections of liver cancer blood samples. Glycotest is in advanced negotiations with a number of prospective collaboration partners, further details of which shall be reported in due course.
In response our share price has gone up by 1p.
You couldn't make it up!
NSCI should be red hot.
Glycotest valuation pretty much confirmed by todays funding news and PDSB signs up a CMO who in his last job signed a $5B deal with Keytruda.
He obviously thinks his 200k share at $4.40 are going to be worth a lot more some time soon!
Buy or top up before the herd arrives because this type of mis price just won't last.
Hi Biffa,
Thanks for your input on the board.
I have been trying to access the B Riley interview you refer to but can't find it. Would it be possible for you to post the appropriate link please?
Update to my update.
So far I have these values from the latest results and recent RNS.
Vortex. £3M
SageTech. £1M
QBot. £4M+
PDSB. £6.5M (@ $6.00)
EpiBone. £1M
DNAME. £1M
Cytrovale £1M. Just raised $84M so our 1% has to be £1M+
Ventive. £1M New.
Deeptech. £1M+ Recent fundraise of £1M+
EMV. £5M (Premiums being paid everywhere for fund /asset managers)£100K/Deeptech.
Others. £2M
Cash. £1M
Total £27.5M + £14.5M (below) = £42M!!!!! or approx £2.00 a share.
Todays MCAP £13.5M @ 60p
The ones above have real world values and are worth more than our Market Cap.
Glycotest is valued at another £11M in the books. Sale/fund raise before end of year.
Proaxis is valued at another £3.5M + in the books. Sale/fund raise before end of year.
All the investments have increased in value over the last year.
PDSB is about to embark on 2 PIII trials. Watch the B. Riley securities 2024 presentation. It beats Keytruda hands down. SP is a joke for the potential it has.
Interest will return to NSCI and when it runs it runs!
From another feed.
In the B Riley interview Frank NEVER mentioned an offering just mentioned 2 types of funding. A partnership and a commercial partnership. Also did anyone notice how much the B Riley interviewer started smiling when Frank started talking about how big the TAM was (100 billion) and that no one at this point has any dominance yet and that WE have the ability to become the dominant player. This is all setting up to become a monster company over the next 3-5 years. Stay strong longs and imo you’ll be RICHLY rewarded.
Not many shares around where there are near term multiple catalysts that could double/triple the share price in one go.
If they don't come in ,well we stay at 50/60p and trundle on with the rest of the portfolio that is growing pretty well.
Happy to position myself for a £200K gain or a £20k bath!
Well its been an interesting 2+ year journey, but alas all BAD things must also come to an end.
Bought this because of the HYPE without really doing any research, when i was just starting off in my trading journey and AIM was all the rage :)
After having lost 66% i'm OUT, as i don't see this going anywhere.
Just goes to show you DO NEED to know what your doing in the market to make money :).
Thank god for my 'Knight in Shiny Armour '- RR. It has made ALL my losses look like ants :) MAY IT CONTINUE :)
Yes, I'm getting the same feeling - and am therefore worried what happens if Glycotest doesn't come through ?!
Personally, I think the success of Glycotest will be the only factor that ignites a rocket up this share. I believe it's 100% owned by NSCI.
Is this ever going to shift ?! It's lifeless......... not exactly being inundated with information on progress are we ?!
Deeptech valued at zero in the recent results so safe to assume a valuation of £1M+ for our 30% stake after this fund raise.
Credit to NSCI for doing what they promised and adding value to the portfolio.
Looks like another valuation uplift coming tomorrow.
Cytovale just raised $84M for it's sepsis test.
On the books we have 1% valued at £400K, giving a company value of £40M!
Worth a damn sight more than £40M after that mega raise.
Yes RP all depends on entry point, fortunately I got loaded up at 50p can only see upside from here PDSB up another 5% as I write.
Lets wait and see - this was one of worst trades i did and im still sitting on a HUGE loss :)
Where’s the herd ? Can’t believe this is still where it is, due a massive re-rate. PDSB and Ventive news is amazing. So undervalued here imho
PDSB conference call today was unreal. No wonder it's up 20% on heavy volume.
8 ongoing P11 trials that cost us nothing.
About to start a couple of P111 and on the cusp of major partnership or full sale.
A billion $ company in the making!
Old but updated post below.
So another £1M+, Q BOT, to add to the pot and no one notices!
Plus another £1M from Ventive.
£23.5M vs £13M M Cap
I do think that PDSB will hit the $1B valuation, $25+, if the readouts continue to impress.
It is not just one drug but the whole platform that will come through.
That will add £20M+ to our valuation and take us over £2.00.
Add in the rest of the investments and 60p is just crazy. If Glycotest comes in you are looking at £3, £4 or £5 a share.
So far I have from the latest results and recent RNS.
Vortex £3M
SageTech £1M
QBot. £3M+. Now £4M+
PDSB. £6.5M (@ $6.00)
DNAME. £1M
Cytrovale £1M
Ventive £1M New.
EMV. £5M (Premiums being paid everywhere for fund /asset managers)
Cash. £1M
Total £21.5M vs MCap of £14M .Now £22.5M ...Now £23.5M...
The ones above have real world values and are worth more than our Market Cap.
Glycotest is valued at another £11M in the books. Sale/fund raise before end of year.
Proaxis is valued at another £3M + in the books. Sale/fund raise before end of year.
Plus another 25 investments.
Insane value
Https://www.investorschronicle.co.uk/ideas/2023/11/06/a-technology-sector-bargain/
GLA